A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms

Acta Psychiatrica Scandinavica

Volumn 99, Issue 3, 1999, Pages 160-170

  Lemmens, Philippe ^a   Brecher, M ^b   Van Baelen, B ^b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b NONE

Author keywords

Double blind studies; Extrapyramidal symptoms; Haloperidol; Risperidone; Schizophrenia; Tardive dyskinesia

Indexed keywords

ANTIPARKINSON AGENT; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO; REMOXIPRIDE; RISPERIDONE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CLINICAL TRIAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0032981228     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1999.tb00972.x     Document Type: Article

References (45)

1. CASEY DE, KEEPERS GA. Neuroleptic side-effects: acute extrapyramidal syndromes and tardive dyskinesia. In: VIBEKE CHRISTENSEN DE, VIBEKE CHRISTENSEN A, ed. Psychopharmacology: current trends. Berlin: Springer, 1988:74-93.
2. CASEY DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109-120.
3. BALDESSARINI RJ, COLE JO, DAVIS JM et al. Tardive dyskinesia: a task force report. Washington, DC: American Psychiatric Press, 1980.
4. KANE JM, SMITH JM. Tardive dyskinesia: prevalence and risk factors 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481.
5. CASEY DE. Tardive dyskinesia. In: MELTZER H, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:1411-1419.
6. CREESE I, BURT DR, SNYDER SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483.
7. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.
8. KAPUR S, REMINGTON G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-476.
9. BLEICH A, BROWN SL, KAHN R, VAN PRAAG H. The role of serotonin in schizophrenia. Schizophr Bull 1988;24:297-315.
10. OWENS DCG. The pharmacology of negative and affective symptoms in psychosis (abstract). Neuropsychopharmacology 1994;10(3S Part 1):151S.
11. 2 receptor blocker. Drug Dev Res 1986;8:295-211.
12. NIEMEGEERS CJ, AWOUTERS F, JANSSEN PA. Antagonisme de la serotonine implique dans l'effet antipsychotique: confirmations par la ritanserine et le risperidone. Encephale 1990;16:147-151.
13. 2 receptor blocking agent. Curr Ther Res 1986;40:492-499.
14. 2 antagonist, on Parkinsonian rest tremor. Curr Ther Res 1987;41:290-300.
15. 2 antagonist ritanserin in neuroleptic-induced parkinsonism: a doubleblind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990;13:500-506.
16. 2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 1996;124:35-39.
17. 2 receptor occupancy levels. Psychiatry Res 1997;75:91-101.
18. MELTZER HY. Clozapine and other atypical neuroleptics: efficacy, side-effects, optimal utilization. J Clin Psychiatry (Monograph Series) 1994;12:38-42.
19. AMSLER HA, TEERENHOVI L, BARTH E et al. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 1977;56:241-248.
20. 2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-693.
21. LEYSEN JE, GOMMEREN W, EENS A, DE CHAFFOY DE, COURCELLES D, STOOF JC, JANSSEN PAJ. The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-670.
22. CHOUINARD G, JONES B, REMINGTON G et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
23. MARDER SR, MEIBACH RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
24. PEUSKENS J and the Risperidone Study Group. Risperidone in the treatment of chronic schizophrenic patients: a multinational, multicentre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, revised 3rd edn (DSM-III-R). Washington, DC: American Psychiatric Association, 1987.
26. CHOUINARD G, ROSS-CHOUINARD A, ANNABEL L, JONES BD. The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233.
27. KAY SR, FISZBEIN A, OPLER LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
28. BORISON RL, PATHIRAJA AP, DIAMOND BI, MEIBACH RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218.
29. CLAUS A, BOLLEN J, DE CUYPER H et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
30. MIN SK, RHE CS, KIM C-E, KANG D-Y. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 1993;34:179-190.
31. BLIN O, AZORIN JM, BOUHOURS P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16:38-44.
32. HØYBERG OJ, FENSBO C, REMVIG J, LINGJAERDE O, SLOTH-NIELSEN M, SALVESEN I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402.
33. HUTTUNEN MO, PIEPPONEN T, RANTANEN H, LARMO I, NYHOLM R, RAITASUO V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a doubleblind parallel-group trial. Acta Psychiatr Scand 1995;91:271-277.
34. BONDOLFI G, DUFOUR H, PATRIS M et al. on behalf of the Risperidone Study Group. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998;155:499-504.
35. NAIR NPV and the Risperidone Study Group. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. J Clin Psychopharmacol 1998;18:103-110.
36. KLIESER E, LEHMANN E, KINZLER E, WURTHMANN C, HEINRICH K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995;15 (Suppl. 1):45S-51S.
37. MÖLLER H-J, GAGIANO CA, ADDINGTON DE, VON KNORRING L, TORRES-PLANK J-F, GAUSSARES C. Long-term treatment with risperidone in patients with chronic schizophrenia. Int Clin Psychopharmacol 1998;13:99-106.
38. CHALMERS TC, LEVIN H, SACKS HS, REITMAN D, BERRIER J, NAGALINGAM R. Meta-analysis of clinical trials as a scientific discipline. I. Control of bias and comparison with large cooperative trials. Stat Med 1987;6:315-325.
39. CAPPELLERI JC, IOANNIDIS JPA, SCHMID CH et al. Large trials v. meta-analysis of smaller trials. How do their results compare? J Am Med Assoc 1996;276:1332-1338.
40. SIMPSON GM, LINDENMAYER J-P. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17:194-201.
41. KHAN BU, GLAZER WM. Risperidone for disturbed behavior and tardive dyskinesia in developmentally disturbed adults. American Psychiatric Association Annual Meeting, New York, 1996. New Research Program and Abstracts: 176.
42. CASEY DE. The differential diagnosis of tardive dyskinesia. Acta Psychiatr Scand 1981;63 (Suppl. 291):71-87.
43. TRAN PV, HAMILTON SH, KUNTZ AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
44. SCHOOLER NR. Comments on article by Tran and colleagues, 'Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders'. J Clin Psychopharmacol 1998;18:174-175.
45. GHEUENS J, GREBB JA. Comments on article by Tran and colleagues, 'Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders'. J Clin Psychopharmacol 1998;18: 176-177.